A year of two halves for US approvals
FDA green lights picked up in the second half, but for the really impressive number look at year-five sales.
Not so fast for some accelerated approvals
The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.
Novartis has the most new approvals, but Lilly’s are worth more
When it comes to big pharma’s novel therapies, it is a case of quantity versus quality.
Brace for an end-of-year boost to drug approvals
The first half of 2022 was slow on the regulatory front, but plenty of big decisions remain for Bristol Myers Squibb, Apellis and others.
